Two Sigma Securities’s CRISPR Therapeutics CRSP Stock Holding History

Two Sigma Securities’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,300	Closed	-$202K	–	1958
2024 Q3	$202K	Sell	4,300 -25,000	-85%	-$1.27M	﹤0.01%	2153
2024 Q2	$1.58M	Buy	29,300 +14,800	+102%	+$856K	0.02%	836
2024 Q1	$988K	Sell	14,500 -22,600	-61%	-$1.62M	0.01%	1141
2023 Q4	$2.32M	Buy	37,100 +26,900	+264%	+$1.49M	0.02%	635
2023 Q3	$463K	Buy	10,200 +4,300	+73%	+$222K	﹤0.01%	1594
2023 Q2	$331K	Buy	+5,900	New	+$335K	﹤0.01%	1783
2023 Q1	–	Sell	-16,300	Closed	-$663K	–	2763
2022 Q4	$663K	Sell	16,300 -16,600	-50%	-$881K	0.02%	908
2022 Q3	$2.15M	Buy	32,900 +24,100	+274%	+$1.75M	0.07%	338
2022 Q2	$535K	Sell	8,800 -3,600	-29%	-$212K	0.02%	861
2022 Q1	$778K	Buy	+12,400	New	+$779K	0.03%	737

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Securities's CRSP Position: Q3 2023 in Review

Two Sigma Securities sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 6,864 shares — an estimated $354K sold.

Two Sigma Securities first reported a position in CRSP in Q2 2021 and held it in 6 quarters. The position peaked at $687K in Q3 2022. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Two Sigma Securities reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
Two Sigma Securities sold 6,864 CRISPR Therapeutics shares in Q3 2023, an estimated $354K.
Two Sigma Securities first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 6 quarters.
Two Sigma Securities's CRISPR Therapeutics position peaked at $687K in Q3 2022.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.